@c2tides: This study looked at two phase 3, placebo-controlled trials in people living with HIV who had excess abdominal fat. Researchers reported that 2 mg daily tesamorelin was associated with a reduction in visceral abdominal fat at 26 weeks compared with placebo. The important part is the context: this wasn’t a general weight-loss study, and the findings came from a very specific clinical population. That’s why reading the actual study matters — not just the headline. At C₂ Tides, we want to make research easier to understand without overhyping what the data actually says.

C2Tides

Open In TikTok:

Region: US

Tuesday 15 September 2026 16:41:39 GMT